DK3773737T3 - Saponin konjugeret til epitop-bindende proteiner - Google Patents

Saponin konjugeret til epitop-bindende proteiner Download PDF

Info

Publication number: DK3773737T3
Authority: DK; Denmark
Prior art keywords: epitope; binding proteins; saponin; conjugated; saponin conjugated
Prior art date: 2018-12-21

Application number

DK19835231.2T

Other languages

English (en)

Inventor

Ruben Postel

Hendrik Fuchs

Original Assignee

Sapreme Tech Bv

Univ Berlin Charite

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-12-21

Filing date

2019-12-09

Publication date

2021-10-04

2019-12-09 Application filed by Sapreme Tech Bv, Univ Berlin Charite filed Critical Sapreme Tech Bv

2021-10-04 Application granted granted Critical

2021-10-04 Publication of DK3773737T3 publication Critical patent/DK3773737T3/da

Links

0 C*C(C)(C)*#N Chemical compound C*C(C)(C)*#N 0.000 description 18
JEHBXJJESBILFK-UHFFFAOYSA-N C=C(C=C1)N(CCCCCC(NN)=O)C1=O Chemical compound C=C(C=C1)N(CCCCCC(NN)=O)C1=O JEHBXJJESBILFK-UHFFFAOYSA-N 0.000 description 2
JCXWNKRSLKCAJC-UHFFFAOYSA-O CCNNC(c1ccc(CCCCN(C(CC2)=O)C2=[ClH])cc1)=[NH2+] Chemical compound CCNNC(c1ccc(CCCCN(C(CC2)=O)C2=[ClH])cc1)=[NH2+] JCXWNKRSLKCAJC-UHFFFAOYSA-O 0.000 description 2
LFPODNJKHGJLRX-UHFFFAOYSA-N OCc(cc1)ccc1C(C1CC1)=O Chemical compound OCc(cc1)ccc1C(C1CC1)=O LFPODNJKHGJLRX-UHFFFAOYSA-N 0.000 description 2
MFUTZCIFSIGPOY-UHFFFAOYSA-N C=C(CC1)NC1O Chemical compound C=C(CC1)NC1O MFUTZCIFSIGPOY-UHFFFAOYSA-N 0.000 description 1
YHCKKXCUZCBAPU-UHFFFAOYSA-N CC(ON(C(CC1)O)C1=O)=O Chemical compound CC(ON(C(CC1)O)C1=O)=O YHCKKXCUZCBAPU-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
- A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Botany (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Dispersion Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK19835231.2T 2018-12-21 2019-12-09 Saponin konjugeret til epitop-bindende proteiner DK3773737T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
NL2022283		2018-12-21
NL2023468		2019-07-10
NL2023568		2019-07-25
PCT/EP2019/000334 WO2020126064A1 (en)	2018-12-21	2019-12-09	Saponin conjugated to epitope-binding proteins

Publications (1)

Publication Number	Publication Date
DK3773737T3 true DK3773737T3 (da)	2021-10-04

Family

ID=71101079

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK21212184.2T DK4015003T3 (da)	2018-12-21	2019-12-09	Forbedret antistof-oligonukleotid-konjugat
DK19835231.2T DK3773737T3 (da)	2018-12-21	2019-12-09	Saponin konjugeret til epitop-bindende proteiner
DK19817673.7T DK3897738T3 (da)	2018-12-21	2019-12-09	Saponin-konjugater

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK21212184.2T DK4015003T3 (da)	2018-12-21	2019-12-09	Forbedret antistof-oligonukleotid-konjugat

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK19817673.7T DK3897738T3 (da)	2018-12-21	2019-12-09	Saponin-konjugater

Country Status (15)

Country	Link
US (7)	US20220054643A1 (da)
EP (14)	EP3808379A1 (da)
JP (6)	JP2022515797A (da)
KR (8)	KR20210117274A (da)
CN (6)	CN113747923A (da)
AU (6)	AU2019411289A1 (da)
BR (2)	BR112021012222A8 (da)
CA (6)	CA3123978A1 (da)
DK (3)	DK4015003T3 (da)
ES (2)	ES2899612T3 (da)
IL (8)	IL284265A (da)
MX (2)	MX2021007296A (da)
PT (1)	PT4015003T (da)
SG (8)	SG11202106574UA (da)
WO (8)	WO2020126627A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2017281497B2 (en)	2016-06-22	2023-04-06	Proqr Therapeutics Ii B.V.	Single-stranded RNA-editing oligonucleotides
JP7373998B2 (ja)	2017-05-02	2023-11-06	コーネル・ユニバーシティー	有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
AU2019411289A1 (en) *	2018-12-21	2021-08-12	Sapreme Technologies B.V.	Improved cell-targeting binding molecule
KR20220038744A (ko) *	2019-07-25	2022-03-29	사프렘 테크놀로지스 비.브이.	치료 윈도우가 개선된 사포닌 유도체
CN113527497B (zh) *	2020-04-16	2022-06-10	上海洛启生物医药技术有限公司	抗Trop2纳米抗体及其应用
US20230365617A1 (en) *	2020-06-24	2023-11-16	Sapreme Technologies B.V.	Saponin derivatives for use in medicine
KR20230043115A (ko) *	2020-06-24	2023-03-30	사프렘 테크놀로지스 비.브이.	히드라존에 기반한 사포닌 유도체
CN116261469A (zh) *	2020-06-24	2023-06-13	萨普雷米科技有限公司	包含含有vhh的adc或aoc和皂苷或配体-皂苷缀合物的组合
WO2021261992A1 (en) *	2020-06-24	2021-12-30	Sapreme Technologies B.V.	Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
CA3183883A1 (en) *	2020-06-24	2021-12-30	Ruben POSTEL	Combination of an antibody-drug conjugate and an antibody-saponin conjugate
JP2023533693A (ja) *	2020-06-24	2023-08-04	サプリームテクノロジーズ，ベー．フェー．	ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用
WO2022055352A1 (en) *	2020-09-10	2022-03-17	Sapreme Technologies B.V.	Semicarbazone-based saponin conjugate
WO2022055351A1 (en) *	2020-09-10	2022-03-17	Sapreme Technologies B.V.	Conjugate of saponin, oligonucleotide and galnac
US10894812B1 (en)	2020-09-30	2021-01-19	Alpine Roads, Inc.	Recombinant milk proteins
US10947552B1 (en)	2020-09-30	2021-03-16	Alpine Roads, Inc.	Recombinant fusion proteins for producing milk proteins in plants
AU2021353004A1 (en)	2020-09-30	2023-04-13	Nobell Foods, Inc.	Recombinant milk proteins and food compositions comprising the same
WO2022164316A1 (en)	2021-01-26	2022-08-04	Sapreme Technologies B.V.	Semicarbazone-based saponin conjugate
EP4355369A1 (en) *	2021-06-18	2024-04-24	Sapreme Technologies B.V.	Conjugate of saponin, oligonucleotide and galnac
WO2023038517A1 (en)	2021-09-09	2023-03-16	Sapreme Technologies B.V.	Semicarbazone-based saponin conjugate
WO2023121447A1 (en) *	2021-12-22	2023-06-29	Sapreme Technologies B.V.	Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
WO2023121445A1 (en)	2021-12-22	2023-06-29	Sapreme Technologies B.V.	Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
CA3240612A1 (en)	2021-12-22	2023-06-29	Miriam Verena Bujny	Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
WO2023121444A1 (en)	2021-12-22	2023-06-29	Sapreme Technologies B.V.	Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
WO2023249473A1 (ko) *	2022-06-24	2023-12-28	주식회사 피노바이오	하나의 항체에 2종의 약물-링커 접합체가 연결된 항체-약물 접합체
WO2024013360A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Oligonucleotides for adar-mediated rna editing and use thereof
EP4331610A1 (en) *	2022-09-01	2024-03-06	Sapreme Technologies B.V.	Polyplex-saponin covalent conjugate
WO2024046622A1 (en) *	2022-09-01	2024-03-07	Sapreme Technologies B.V.	Compositions of polyplexes and saponins
EP4331609A1 (en) *	2022-09-01	2024-03-06	Sapreme Technologies B.V.	Methods and compositions for enhanced polyplex delivery

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5591829A (en) *	1987-05-29	1997-01-07	Matsushita; Shuzo	Antibodies modified with toxic substance
US5583112A (en) *	1987-05-29	1996-12-10	Cambridge Biotech Corporation	Saponin-antigen conjugates and the use thereof
US5856571A (en) *	1995-06-07	1999-01-05	Cellpro, Incorporated	Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
AU732856B2 (en) *	1997-05-20	2001-05-03	Galenica Pharmaceuticals, Inc.	Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6262029B1 (en) *	1998-08-14	2001-07-17	Galenica Pharmaceuticals, Inc.	Chemically modified saponins and the use thereof as adjuvants
EP1476018A4 (en) *	2002-02-04	2005-09-21	Corixa Corp	IMMUNOSTIMULANT COMPOSITIONS BASED ON PHOSPHATES OF AMINOALKYL GLUCOSAMINIDE AND SAPONINS
CA2522213A1 (en) *	2003-04-08	2004-10-28	Dante J. Marciani	Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
ES2395818T3 (es) *	2004-07-13	2013-02-15	Charite - Universitatsmedizin Berlin	Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina
JP2008510829A (ja) *	2004-08-25	2008-04-10	ザリージェンツオブザユニバーシティオブミシガン	デンドリマーに基づく組成物およびそれらの使用法
US10155816B2 (en)	2005-11-28	2018-12-18	Genmab A/S	Recombinant monovalent antibodies and methods for production thereof
ES2630205T3 (es) *	2006-11-20	2017-08-18	Duecom	Uso de partículas que contengan lípidos que comprenden saponínas quillaja para el tratamiento del cáncer
WO2008109105A2 (en) *	2007-03-06	2008-09-12	Flagship Ventures	Methods and compositions for improved therapeutic effects with sirna
WO2009117828A1 (en) *	2008-03-26	2009-10-01	National Research Counsil Of Canada	Saponin extract from saponaria spp. and uses thereof
US8309614B2 (en) *	2008-04-11	2012-11-13	Cedars-Sinai Medical Center	Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery
WO2011054811A1 (en) *	2009-11-03	2011-05-12	Santaris Pharma A/S	Rna antagonists targeting hsp27 combination therapy
KR20130062931A (ko) *	2010-05-13	2013-06-13	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	핵 호르몬 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
US9125835B2 (en) *	2010-11-12	2015-09-08	Rutgers, The State University Of New Jersey	Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases
CN102652836A (zh) *	2011-03-03	2012-09-05	华中科技大学同济医学院附属协和医院	靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法
KR20140114826A (ko) *	2011-12-14	2014-09-29	시애틀 지네틱스, 인크.	Fgfr 항체 약물 콘주게이트 (adcs) 및 그의 용도
EP2922575B1 (en) *	2012-11-26	2019-06-26	President and Fellows of Harvard College	Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
AR095962A1 (es) *	2013-04-01	2015-11-25	Moreinx Ab	Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
GB201400994D0 (en) *	2014-01-21	2014-03-05	Ucl Business Plc	Drug delivery system
TW201617368A (zh) *	2014-09-05	2016-05-16	史坦森特瑞斯公司	新穎抗ｍｆｉ２抗體及使用方法
CN106892957B (zh) *	2015-12-17	2018-11-16	广州中医药大学	一种齐墩果烷型三萜皂苷类化合物及其制备方法和应用
US20200338209A1 (en) *	2016-06-08	2020-10-29	Abbvie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates
AU2019411289A1 (en) *	2018-12-21	2021-08-12	Sapreme Technologies B.V.	Improved cell-targeting binding molecule
WO2022055352A1 (en) *	2020-09-10	2022-03-17	Sapreme Technologies B.V.	Semicarbazone-based saponin conjugate

2019
- 2019-12-09 AU AU2019411289A patent/AU2019411289A1/en active Pending
- 2019-12-09 WO PCT/EP2019/084292 patent/WO2020126627A1/en unknown
- 2019-12-09 CN CN201980092673.5A patent/CN113747923A/zh active Pending
- 2019-12-09 KR KR1020217023071A patent/KR20210117274A/ko unknown
- 2019-12-09 US US17/312,193 patent/US20220054643A1/en active Pending
- 2019-12-09 WO PCT/EP2019/084210 patent/WO2020126609A2/en unknown
- 2019-12-09 KR KR1020217023063A patent/KR20210119978A/ko unknown
- 2019-12-09 US US17/312,476 patent/US20220072149A1/en active Pending
- 2019-12-09 US US17/312,311 patent/US20230173085A1/en active Pending
- 2019-12-09 CN CN201980092811.XA patent/CN113474010A/zh active Pending
- 2019-12-09 CA CA3123978A patent/CA3123978A1/en active Pending
- 2019-12-09 DK DK21212184.2T patent/DK4015003T3/da active
- 2019-12-09 WO PCT/EP2019/084180 patent/WO2020126600A1/en unknown
- 2019-12-09 CA CA3124065A patent/CA3124065A1/en active Pending
- 2019-12-09 KR KR1020217023076A patent/KR20210117276A/ko unknown
- 2019-12-09 JP JP2021536414A patent/JP2022515797A/ja active Pending
- 2019-12-09 US US17/312,403 patent/US20220111066A1/en active Pending
- 2019-12-09 SG SG11202106574UA patent/SG11202106574UA/en unknown
- 2019-12-09 JP JP2021536412A patent/JP2022515251A/ja active Pending
- 2019-12-09 SG SG11202106572QA patent/SG11202106572QA/en unknown
- 2019-12-09 PT PT212121842T patent/PT4015003T/pt unknown
- 2019-12-09 US US17/415,759 patent/US20220218837A1/en active Pending
- 2019-12-09 AU AU2019411278A patent/AU2019411278A1/en active Pending
- 2019-12-09 US US17/312,019 patent/US20220313834A1/en active Pending
- 2019-12-09 CA CA3124064A patent/CA3124064A1/en active Pending
- 2019-12-09 SG SG11202106603UA patent/SG11202106603UA/en unknown
- 2019-12-09 CN CN201980092858.6A patent/CN113474009A/zh active Pending
- 2019-12-09 EP EP20209450.4A patent/EP3808379A1/en active Pending
- 2019-12-09 EP EP23166479.8A patent/EP4223316A3/en active Pending
- 2019-12-09 BR BR112021012222A patent/BR112021012222A8/pt not_active Application Discontinuation
- 2019-12-09 SG SG11202106664PA patent/SG11202106664PA/en unknown
- 2019-12-09 SG SG11202106606RA patent/SG11202106606RA/en unknown
- 2019-12-09 EP EP19817689.3A patent/EP3897735A1/en active Pending
- 2019-12-09 WO PCT/EP2019/084242 patent/WO2020126620A2/en active Search and Examination
- 2019-12-09 JP JP2021536407A patent/JP2022516043A/ja active Pending
- 2019-12-09 EP EP19817673.7A patent/EP3897738B1/en active Active
- 2019-12-09 KR KR1020217023074A patent/KR20210117275A/ko unknown
- 2019-12-09 AU AU2019400630A patent/AU2019400630A1/en active Pending
- 2019-12-09 SG SG11202106672SA patent/SG11202106672SA/en unknown
- 2019-12-09 JP JP2021536411A patent/JP2022516044A/ja active Pending
- 2019-12-09 CA CA3124151A patent/CA3124151A1/en active Pending
- 2019-12-09 CN CN201980092610.XA patent/CN113498350A/zh active Pending
- 2019-12-09 EP EP23170913.0A patent/EP4241847A3/en active Pending
- 2019-12-09 SG SG11202106612QA patent/SG11202106612QA/en unknown
- 2019-12-09 ES ES19835231T patent/ES2899612T3/es active Active
- 2019-12-09 KR KR1020217023075A patent/KR20210107073A/ko unknown
- 2019-12-09 AU AU2019408811A patent/AU2019408811A1/en active Pending
- 2019-12-09 KR KR1020217023069A patent/KR20210119979A/ko unknown
- 2019-12-09 EP EP19817676.0A patent/EP3897742A2/en active Pending
- 2019-12-09 WO PCT/EP2019/000334 patent/WO2020126064A1/en unknown
- 2019-12-09 EP EP19817682.8A patent/EP3856254A2/en active Pending
- 2019-12-09 EP EP21212184.2A patent/EP4015003B1/en active Active
- 2019-12-09 WO PCT/EP2019/084190 patent/WO2020126604A1/en active Search and Examination
- 2019-12-09 WO PCT/EP2019/084290 patent/WO2020126626A1/en unknown
- 2019-12-09 JP JP2021536413A patent/JP2022516045A/ja active Pending
- 2019-12-09 WO PCT/EP2019/084211 patent/WO2020126610A1/en unknown
- 2019-12-09 SG SG11202106575YA patent/SG11202106575YA/en unknown
- 2019-12-09 US US17/312,104 patent/US20220023433A1/en active Pending
- 2019-12-09 EP EP19817677.8A patent/EP3897739B1/en active Active
- 2019-12-09 KR KR1020217022975A patent/KR20210110323A/ko unknown
- 2019-12-09 CN CN201980092709.XA patent/CN113507941A/zh active Pending
- 2019-12-09 DK DK19835231.2T patent/DK3773737T3/da active
- 2019-12-09 EP EP19835231.2A patent/EP3773737B1/en active Active
- 2019-12-09 BR BR112021012225A patent/BR112021012225A8/pt unknown
- 2019-12-09 CA CA3124406A patent/CA3124406A1/en active Pending
- 2019-12-09 AU AU2019411276A patent/AU2019411276A1/en active Pending
- 2019-12-09 JP JP2021536410A patent/JP7502301B2/ja active Active
- 2019-12-09 EP EP24169240.9A patent/EP4374927A2/en active Pending
- 2019-12-09 AU AU2019407234A patent/AU2019407234A1/en active Pending
- 2019-12-09 CN CN201980092771.9A patent/CN113453722A/zh active Pending
- 2019-12-09 DK DK19817673.7T patent/DK3897738T3/da active
- 2019-12-09 EP EP19820708.6A patent/EP3897741A1/en active Pending
- 2019-12-09 EP EP19817672.9A patent/EP3897743A1/en active Pending
- 2019-12-09 KR KR1020217023032A patent/KR20210119976A/ko unknown
- 2019-12-09 ES ES21212184T patent/ES2952017T3/es active Active
- 2019-12-09 EP EP21186481.4A patent/EP3915587A1/en active Pending
- 2019-12-09 CA CA3124129A patent/CA3124129A1/en active Pending
- 2019-12-09 MX MX2021007296A patent/MX2021007296A/es unknown
- 2019-12-09 MX MX2021007449A patent/MX2021007449A/es unknown
2021
- 2021-06-21 IL IL284265A patent/IL284265A/en unknown
- 2021-06-21 IL IL284272A patent/IL284272A/en unknown
- 2021-06-21 IL IL284278A patent/IL284278A/en unknown
- 2021-06-21 IL IL284273A patent/IL284273A/en unknown
- 2021-06-21 IL IL284276A patent/IL284276A/en unknown
- 2021-06-21 IL IL284280A patent/IL284280A/en unknown
- 2021-06-21 IL IL284279A patent/IL284279A/en unknown
- 2021-06-21 IL IL284274A patent/IL284274A/en unknown

Also Published As

Publication number	Publication date
CA3124065A1 (en)	2020-06-25
AU2019411289A1 (en)	2021-08-12
EP3773737B1 (en)	2021-09-01
SG11202106612QA (en)	2021-07-29
SG11202106606RA (en)	2021-07-29
EP3897738A1 (en)	2021-10-27
EP3897738B1 (en)	2024-01-24
ES2952017T3 (es)	2023-10-26
EP4223316A2 (en)	2023-08-09
US20220023433A1 (en)	2022-01-27
IL284280A (en)	2021-08-31
KR20210119978A (ko)	2021-10-06
AU2019408811A2 (en)	2021-09-02
CA3124151A1 (en)	2020-06-25
WO2020126620A3 (en)	2020-07-23
EP3897741A1 (en)	2021-10-27
EP3897742A2 (en)	2021-10-27
BR112021012225A2 (da)	2021-11-30
EP3897735A1 (en)	2021-10-27
KR20210117276A (ko)	2021-09-28
EP3856254A2 (en)	2021-08-04
EP3808379A1 (en)	2021-04-21
CN113507941A (zh)	2021-10-15
EP3773737A1 (en)	2021-02-17
WO2020126626A1 (en)	2020-06-25
JP2022515251A (ja)	2022-02-17
US20220313834A1 (en)	2022-10-06
CN113747923A (zh)	2021-12-03
CN113453722A (zh)	2021-09-28
CA3124406A1 (en)	2020-06-25
AU2019407234A2 (en)	2021-08-26
SG11202106664PA (en)	2021-07-29
WO2020126609A2 (en)	2020-06-25
EP3897739A1 (en)	2021-10-27
WO2020126609A3 (en)	2020-08-13
US20220111066A1 (en)	2022-04-14
SG11202106572QA (en)	2021-07-29
AU2019411289A2 (en)	2021-08-26
SG11202106603UA (en)	2021-07-29
IL284274A (en)	2021-08-31
EP3915587A1 (en)	2021-12-01
IL284272A (en)	2021-08-31
AU2019411278A1 (en)	2021-08-12
WO2020126620A2 (en)	2020-06-25
EP4223316A3 (en)	2023-10-04
KR20210119976A (ko)	2021-10-06
EP4241847A3 (en)	2023-10-04
EP3897739C0 (en)	2024-04-17
KR20210119979A (ko)	2021-10-06
JP2022515797A (ja)	2022-02-22
JP2022516043A (ja)	2022-02-24
BR112021012222A8 (pt)	2023-04-25
WO2020126600A1 (en)	2020-06-25
WO2020126610A1 (en)	2020-06-25
EP4015003B1 (en)	2023-05-10
WO2020126604A1 (en)	2020-06-25
KR20210117274A (ko)	2021-09-28
EP3897739B1 (en)	2024-04-17
KR20210107073A (ko)	2021-08-31
EP4374927A2 (en)	2024-05-29
AU2019407234A1 (en)	2021-08-19
US20220054643A1 (en)	2022-02-24
US20220218837A1 (en)	2022-07-14
EP3897743A1 (en)	2021-10-27
AU2019411276A1 (en)	2021-08-12
AU2019400630A2 (en)	2021-08-26
SG11202106672SA (en)	2021-07-29
CN113474009A (zh)	2021-10-01
JP2022515250A (ja)	2022-02-17
MX2021007296A (es)	2021-12-10
BR112021012225A8 (pt)	2023-04-25
EP4241847A2 (en)	2023-09-13
US20230173085A1 (en)	2023-06-08
IL284279A (en)	2021-08-31
CN113498350A (zh)	2021-10-12
JP7502301B2 (ja)	2024-06-18
DK4015003T3 (da)	2023-06-12
IL284276A (en)	2021-08-31
DK3897738T3 (da)	2024-02-19
CA3124064A1 (en)	2020-06-25
EP4015003A1 (en)	2022-06-22
WO2020126627A1 (en)	2020-06-25
ES2899612T3 (es)	2022-03-14
BR112021012222A2 (da)	2021-11-30
WO2020126064A1 (en)	2020-06-25
KR20210117275A (ko)	2021-09-28
AU2019400630A1 (en)	2021-08-12
AU2019408811A1 (en)	2021-08-12
CA3124129A1 (en)	2020-06-25
PT4015003T (pt)	2023-07-17
JP2022516045A (ja)	2022-02-24
US20220072149A1 (en)	2022-03-10
SG11202106575YA (en)	2021-07-29
WO2020126610A9 (en)	2020-09-24
CN113474010A (zh)	2021-10-01
JP2022516044A (ja)	2022-02-24
MX2021007449A (es)	2021-12-10
IL284278A (en)	2021-08-31
KR20210110323A (ko)	2021-09-07
CA3123978A1 (en)	2020-06-25
SG11202106574UA (en)	2021-07-29
IL284265A (en)	2021-08-31
IL284273A (en)	2021-08-31

Publication	Publication Date	Title
DK3773737T3 (da)	2021-10-04	Saponin konjugeret til epitop-bindende proteiner
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
DK3625259T3 (da)	2024-07-08	Anti-sirpalpha-antistoffer
DK3548652T3 (da)	2024-07-08	Fremgangsmåder til proteinanalyse
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
KR102355950B9 (ko)	2023-10-26	Tigit에 대한 항체
DK3538864T3 (da)	2023-06-06	Mikrotom
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA42626A (fr)	2018-06-20	Nouveaux anticorps anti-pd-1
DK3307274T3 (da)	2020-11-09	Anti-cd123-antistoffer og konjugater deraf
DK3313884T3 (da)	2021-02-22	Anti-cd123-antistoffer og konjugater og derivater deraf
DK3810602T3 (da)	2023-12-11	Forbindelser
DK3723783T3 (da)	2023-03-20	Mitokondrie-målrettede peptider
DK3298718T3 (da)	2020-02-03	Teknikker til signal-forlængelsessignalering
DK3606961T3 (da)	2022-07-04	Garp-tgf-beta-antistoffer
CL2018000520A1 (es)	2018-12-07	Proteinas inhibidoras de insectos novedosas
DK3420361T3 (da)	2023-01-23	Massespektrometrikit
MA52152A (fr)	2021-01-20	Anticorps
MA42843A (fr)	2018-07-25	Anticorps anti-cd115
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
DK3216395T3 (da)	2021-10-25	Analytmåleplaster
MA52349A (fr)	2021-03-03	Proteines de levures
DK3494116T3 (da)	2020-01-27	Østrogenreceptormodulatorer